Betaine‐homocysteine Methyltransferase Pharmacogenetics: Human Liver Genotype‐phenotype Association Study

Qiping Feng,Krishna Kalari,Brooke L. Fridley,Gregory Jenkins,Jianping Zhang,Monica Nye Johnson,Richard M. Weinshilboum
DOI: https://doi.org/10.1096/fasebj.24.1_supplement.756.2
2010-01-01
Abstract:ObjectivesBetaine‐homocysteine methyltransferase (BHMT) catalyzes the remethylation of homocysteine. BHMT in the human liver is responsible for up to 25% of homocysteine metabolism. Knowledge of the relationship between genetic polymorphisms and BHMT phenotypes could enhance our understanding of the role of this reaction in drug metabolism.MethodsLevels of BHMT enzyme activity and immunoreactive protein were measured in 268 human liver biopsies. Twelve tag BHMT SNPs from our own gene resequencing and HapMap data were used to genotype DNA from these samples. Genotype‐phenotype association analysis was then performed. BHMT enzyme activity averaged 0.077 ± 0.028 units/μg, with a 12 fold variation.ResultsBHMT protein levels averaged 6.9 ± 3.3 units/μg, with a 50‐fold variation. Three SNPs (rs41272270, rs16876512, and rs6875201), located 28kb upstream, in the 5′‐UTR and in intron 1 of BHMT, respectively, were significantly correlated with both phenotypes (p<10−8 for enzyme activity and p<10−5 for protein level). rs41272270 was associated with altered protein binding during electrophoresis mobility shift assay.ConclusionsThree tag SNPs were significantly associated with human hepatic BHMT enzyme activity and immunoreactive protein. These observations may help us understand the regulation of BHMT in the human liver and its role in drug metabolism. Supported by NIH U01 GM61388, R01 GM28157, R01 CA132780.
What problem does this paper attempt to address?